Charles Schwab Investment Management Inc. Increases Position in Sanofi (NASDAQ:SNY)

Charles Schwab Investment Management Inc. boosted its stake in shares of Sanofi (NASDAQ:SNY) by 31.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 139,505 shares of the company’s stock after buying an additional 33,105 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Sanofi were worth $8,040,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. GFS Advisors LLC lifted its holdings in shares of Sanofi by 1,017.9% in the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after acquiring an additional 11,655 shares during the last quarter. Legacy Capital Wealth Partners LLC grew its position in shares of Sanofi by 114.2% in the 3rd quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock worth $1,399,000 after buying an additional 12,942 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its position in Sanofi by 15.2% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company’s stock worth $5,673,000 after purchasing an additional 15,439 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Sanofi during the 3rd quarter worth approximately $8,728,000. Finally, Strategic Financial Concepts LLC acquired a new stake in Sanofi during the 2nd quarter valued at approximately $1,256,000. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Down 0.7 %

Sanofi stock opened at $48.08 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The company has a market cap of $122.02 billion, a PE ratio of 24.71, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. The stock’s 50 day moving average price is $51.71 and its 200 day moving average price is $52.12.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same period in the prior year, the firm posted $2.55 earnings per share. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, sell-side analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on SNY shares. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.